Editorials

Osteonecrosis of the Jaw and Rheumatoid Arthritis. Is It the Disease or the Drugs? R. Landesberg, P. Taxel. 749
Prevention of Rheumatoid Arthritis: The Very First Steps A. Masetto, M-C. Beaulieu, G. Boire. 752
The Real World of Gout R. Conway. 755
Jeopardizing Validity by Mismeasurement of Quality of Life J. Richardson, N.A. Day. 758

Review

Reaching the Threshold: A Multilayer Pathogenesis of Macrophage Activation Syndrome R. Strippoli, I. Caiello, F. De Benedetti. 761

Articles

Longterm Safety and Efficacy of Tocilizumab in Patients with RA: A Cumulative Analysis of Up to 4.6 Years of Exposure M.C. Genovese, A. Rubbert-Roth, J.S. Smolen, et al. 768
Safety of Abatacept Administered Intravenously in Treatment of RA: Integrated Analyses of up to 8 Years of Treatment from the Abatacept Clinical Trial Program M.E. Weinblatt, L.W. Moreland, R. Westhovens, et al. 787
Association of Polymorphisms Modulating LDL Cholesterol with Susceptibility, Severity, and Progression of RA Y-J. Park, S-A. Yoo, S. Choi, et al. 798
First-degree Relatives of Patients with RA Exhibit High Prevalence of Joint Symptoms I. Smolik, D.B. Robinson, C.N. Bernstein, H.S. El-Gabalawy 818
HDL Profiling Changes in Patients with RA Treated with TNF Inhibitors: A Cohort Study A. Jamnitski, J.H. Levels, I.A. van den Oever, M.T. Nurmohamed. 825
Association of Gastroesophageal Factors and Worsening of Forced Vital Capacity in SSC X.J. Zhang, A. Bonner, M. Hudson, the Scleroderma Research Group, M. Baron, J. Pope. 850
Soluble Biomarkers Associated with Response to Treatment with TNF Inhibitors in PsA V. Chandran, H. Shen, R.A. Pollock, et al. 866
Efficacy and Tolerability of Probencid as Urate-lowering Therapy in Gout; Clinical Experience in High-prevalence Population K. Pui, P.J. Gow, N. Dalbeth. 872
Expression of PPAR α, β, γ and H- and L-Prostaglandin D Synthase During OA in the Spontaneous Hartley Guinea Pig and Experimental Dog Models S-S. Nebbaki, F.E. El Mansouri, H. Afif, et al. 877
Kynurenic Acid in Synovial Fluid and Serum of Patients with RA, SpA, and OA J. Parada-Turska, W. Zgrajek, M. Majdan. 903
Statin Use in Giant Cell Arteritis: A Retrospective Study J. Schmidt, T.A. Kermani, F. Muratore, C.S. Crowson, E.L. Matteson, K.J. Warrington. 910

Contents continued opposite inside back cover...
Antibiotics for Treatment of ReA: A Systematic Review and Metaanalysis  C.E. Barber, J. Kim, R.D. Inman, J.M. Esdaile, M.T. James  ...................................................... 916

Pediatric
Childhood-onset Eosinophilic Granulomatosis with Polyangiitis (formerly Churg-Strauss Syndrome):
A Contemporary Single-center Cohort
S. Gendelman, A. Zeft, S.J. Spalding  ......................... 929

Race, Ethnicity, and Disease Outcomes in JIA:
A Cross-sectional Analysis of the Childhood Arthritis and Rheumatology Research Alliance (CARRA) Registry
S. Ringold, T. Beukelman, P.A. Nigrovic, Y. Kimura, for the Carra Registry Investigators  ......................... 936

Etanercept Improves Lipid Profile and Oxidative Stress Measures in Patients with JIA

Images in Rheumatology
Infectious Tenosynovitis in a Patient with Dermatopolymyositis and Vasculitis
C. Canella, M. Pacheco, F. Costa, E. Marchiori  ............. 949

Canadian Rheumatology Association Meeting
Ottawa, Ontario, Canada
February 13–16, 2013
Abstracts  ................................................................. 950

Letters
CCL18 Activates Fibroblast-like Synoviocytes in Patients with RA
A. Takayasu, Y. Miyabe, W. Yokoyama, et al. ................. 1026

Cyclophosphamide Exposure in Pediatric SLE Is Associated with Reduced Serum Anti-Müllerian Hormone Levels

Meetings in Rheumatology  .......................................... x